At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Clonidine Patch +1 moredrug
Likely dose
Clonidine patch 0.1 mg/week for 3 monthsAI-extracted
Key inclusion· 1
- ✓Diagnosis of heart failure
Key exclusion· 4
- ✕Currently receiving Coumadin therapy
- ✕Myocardial infarction within 3 months before study entry
- ✕Medically unable to receive clonidine
- ✕Advanced kidney or liver disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clonidine and the Skeletal Myopathy of Heart Failure
In Brief
A Phase 4 clinical trial evaluating Clonidine Patch and Matching Placebo Patch for Heart Failure. Completed, enrolled 11 participants across 1 site.
Detailed Summary
People with heart failure often have weakness in their leg muscles. This study will determine whether the leg weakness is due to very high adrenaline levels and whether the medication clonidine can improve leg weakness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedMar 2009
Primary CompletionMar 2011
Study CompletionDec 2012
TodayJul 2026
First PostedMar 10, 2009
Enrollment StartMay 1, 2008
Primary CompletionMar 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.3 years ago
Interventions
Clonidine Patchdrug
A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
Matching Placebo Patchother
A matching placebo patch to be worn for a period of 3 months.